{"id":1516,"date":"2022-06-10T07:17:00","date_gmt":"2022-06-10T07:17:00","guid":{"rendered":"https:\/\/d.ptpl.dev\/acarix\/acarix-signs-additional-commercial-agreement-in-us-and-receives-order-for-cadscorsystem-in-louisiana\/"},"modified":"2024-08-06T12:25:00","modified_gmt":"2024-08-06T12:25:00","slug":"acarix-signs-additional-commercial-agreement-in-us-and-receives-order-for-cadscorsystem-in-louisiana","status":"publish","type":"post","link":"https:\/\/d.ptpl.dev\/acarix\/acarix-signs-additional-commercial-agreement-in-us-and-receives-order-for-cadscorsystem-in-louisiana\/","title":{"rendered":"Acarix signs additional commercial agreement in US and receives order for CADScor\u00aeSystem in Louisiana."},"content":{"rendered":"
\n

Press release<\/strong>\u00a0<\/strong>
Malm\u00f6, Sweden, June 10, 2022\u00a0\u00a0<\/p>\n

Acarix <\/strong>signs <\/strong>additional <\/strong>commercial agreement<\/strong> in US <\/strong>a<\/strong>nd <\/strong>receives <\/strong>order for <\/strong>CADScor\u00aeSystem <\/strong>in Louisiana.<\/strong><\/p>\n

Acarix<\/strong> continues the US expansion with <\/strong>another<\/strong> commercial <\/strong>partnership <\/strong>now <\/strong>covering<\/strong> Louisiana and parts of Mississippi. This pa<\/strong>rtnership <\/strong>with <\/strong>Bio<\/strong>-Rhythms<\/strong> Inc<\/strong> provides access to <\/strong>cardiology clinics, emergency departments and primary care clinics in <\/strong>geographic <\/strong>areas with high medical need for rapid and cost-effective <\/strong>rule-out of <\/strong>coronary artery disease. <\/strong><\/p>\n

Louisiana is among the top 5 US states based on death due to heart disease. The volume of patients and the need for rapid assessment and rapid rule out is high. Acarix\u2019s CADScor\u00aeSystem has a strong potential to be a valuable aid in the rapid assessment of these patients and rule out those at low risk, creating more efficiency and focus on patients that need cardiovascular medical attention.<\/p>\n

\u201cMy cardiology practice at Louisiana Heart Center is very busy and we welcome this new technology to help assess patients quickly. We have received reimbursement payments from insurance companies, which indicate their validation of the technology. With the CADScor\u00aeSystem, we expect to be able to give patients at low-risk rapid response and peace of mind, while we also starting to see greater efficiency in the cardiac care that we provide to our patients\u201d says Dr Marc Bernstein, MD, FACC, FCCP, FSCAI in Slidell, Louisiana.<\/p>\n

\u00a0\u201cI am delighted to be working with Acarix on introducing CADScor\u00aeSystem in Louisiana and Mississippi. The novel AI based acoustic technology brings significant value to physicians assessing chest pain patients. I have been in cardiology sales for 40 years and have not seen such game changing technology since the introduction of balloon angioplasty.\u201d comments Robin Karas, President at Bio-Rhythms, Inc.<\/p>\n

\u201cI am very impressed with the network and relationships that Bio-Rhythms has with our key audiences. Working together with Bio-Rhythms, we will not only be able to impact patients\u2019 lives, but also cardiac care delivery in these states\u201d, comments Helen Ljungdahl Round, President and CEO of Acarix.<\/p>\n

For more information contact:<\/strong>
Helen Ljungdahl Round, CEO, phone +1 267 809 1225, email: helen.round@acarix.com<\/p>\n

The information was provided, through the agency of the above contact person, for publication at the time specified by the company's news distributor, GlobeNewswire.<\/p>\n

About Acarix:<\/strong>\u00a0
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of coronary artery disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor\u00aeSystem is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor\u00aeSystem calculates a patient-specific CAD-score non-invasively in less than 10 minutes and can help rule out more than one third of patients with at least 96% certainty (in a population with approx. 10% CAD prevalence). Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121\u202f576 90, certifiedadviser@redeye.se) is Certified Advisor of Acarix. For more information, please visit\u202fwww.acarix.com.<\/p>\n<\/p>\n

\n <\/div>\n

\n

Attachments<\/strong><\/p>\n\n

PR_Acarix_LA and MS_US_Eng<\/a><\/p>\n<\/div>\n

<\/div>\n